New Report Covers Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.

Complete report available @ Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)
- The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects
- The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

AB2 Bio Ltd. Allergan Plc Ascendia Pharmaceuticals LLC Chong Kun Dang Pharmaceutical Corp. Digna Biotech, S.L. Dompe Farmaceutici S.p.A. HanAll Biopharma Co., Ltd. Herantis Pharma Plc Huons Co., Ltd. InSite Vision Incorporated Kala Pharmaceuticals, Inc. Kissei Pharmaceutical Co., Ltd. KPI Therapeutics, Inc. Kukje Pharmaceutical Industry Co., Ltd. Laboratoires Thea S.A. Lee's Pharmaceutical Holdings Limited Lipicard Technologies Limited Merck & Co., Inc. Mimetogen Pharmaceuticals Inc. Mitotech S.A. Nanomerics Ltd Neuroptis Biotech Novaliq GmbH Ocular Therapeutix, Inc. Oculis ehf OncoNOx ApS Otsuka Holdings Co., Ltd. Parion Sciences, Inc. Quorum Innovations LLC RegeneRx Biopharmaceuticals, Inc. Rigel Pharmaceuticals, Inc. Samjin Pharmaceutical Co., Ltd. Santen Pharmaceutical Co., Ltd. Seikagaku Corporation Sucampo Pharmaceuticals, Inc. TearSolutions, LLC. TopiVert Ltd Xigen SA

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###